Kopran Ltd (KOPRAN) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524280 | NSE: KOPRAN | Pharmaceuticals & Drugs | Small Cap

Kopran Share Price

135.60 -4.10 -2.93%
as on 05-Dec'25 16:59

Kopran Ltd (KOPRAN) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524280 | NSE: KOPRAN | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Kopran

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Kopran stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
43.44
Market Cap:
674.6 Cr.
52-wk low:
123.8
52-wk high:
227.1

Is Kopran Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Kopran: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Kopran Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 9.5%9.5%5.3%8.7%8%13.6%5.6%9.4%11.4%8.6%-
Value Creation
Index
-0.3-0.3-0.6-0.4-0.40.0-0.6-0.3-0.2-0.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 187182154197179223205273337271242
Sales YoY Gr.--3.1%-15.3%27.9%-8.8%24.3%-8.2%33.5%23.6%-19.7%-
Adj EPS 2.80.603.12.64.11.86.46.65.23.2
YoY Gr.--77.8%-96.8%15250%-14%54.2%-54.8%249.5%1.9%-21.2%-
BVPS (₹) 43.546.547.650.553.157.178.682.186.38986.2
Adj Net
Profit
12.12.70.113.311.417.68.93131.624.916
Cash Flow from Ops. 18.74.212.511.81048.8-37.816.93523.3-
Debt/CF from Ops. 1.813.44.24.24.60.3-11.70.71.9-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 4.2%8.6%9.8%-19.7%
Adj EPS 7.1%14.3%41%-21.2%
BVPS8.3%10.9%4.3%3.2%
Share Price 5.4% -0% -6.3% -36.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
6.31.406.35.17.42.887.85.93.7
Op. Profit
Mgn %
13.39.64.711.813.113.57.510.410.914.311.9
Net Profit
Mgn %
6.41.50.16.86.47.94.311.49.49.26.4
Debt to
Equity
0.20.30.30.20.20.10.10.10.10.10
Working Cap
Days
267188233186229187236231204255156
Cash Conv.
Cycle
2254842845587837311074

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Kopran Ltd.

Standalone Consolidated
TTM EPS (₹) 3.2 3.6
TTM Sales (₹ Cr.) 242 592
BVPS (₹.) 86.2 103.8
Reserves (₹ Cr.) 368 453
P/BV 1.62 1.35
PE 43.44 38.33
From the Market
52 Week Low / High (₹) 123.75 / 227.10
All Time Low / High (₹) 6.40 / 558.84
Market Cap (₹ Cr.) 675
Equity (₹ Cr.) 48.3
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Kopran:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Kopran - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Kopran

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales187182154197179223205273337271
Operating Expenses 162164146174156193189245301232
Manufacturing Costs22262830293137394546
Material Costs103957710286121107156205131
Employee Cost 16191820201821252630
Other Costs 22242321212325252525
Operating Profit 2517723233015283739
Operating Profit Margin (%) 13.3%9.6%4.7%11.5%12.9%13.5%7.5%10.2%10.9%14.3%
Other Income 19103210816176
Interest 101075643354
Depreciation 3333344455
Exceptional Items -1000000000
Profit Before Tax 1113717163316374536
Tax 05245946109
Profit After Tax 119513112312313527
PAT Margin (%) 6.1%4.7%3.1%6.6%6.3%10.5%5.7%11.4%10.3%9.9%
Adjusted EPS (₹)2.62.01.13.02.65.42.46.57.25.6
Dividend Payout Ratio (%)0%0%0%0%0%28%123%46%42%54%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 197201206218230247379396416430
Share Capital 52434343434348484848
Reserves 145158162175186204331347368382
Minority Interest0000000000
Debt29504541361637282345
Long Term Debt222822221022224
Short Term Debt7222419271335262041
Trade Payables36362932324030625246
Others Liabilities 18191724282219202125
Total Liabilities 279306297316326324464506511546

Fixed Assets

Gross Block83434551566568738297
Accumulated Depreciation483710131721263035
Net Fixed Assets 35393842434746475261
CWIP 0487733457
Investments 156157157158158159259260261263
Inventories28253025412842484956
Trade Receivables20382045424959848892
Cash Equivalents 42211333721
Others Assets 35404239333552614846
Total Assets 279306297316326324464506511546

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 19412121049-38173523
PBT 1113717163316374536
Adjustment 1316631274-937
Changes in Working Capital -6-243-5-1414-55-5-2-9
Tax Paid -0-1-3-4-4-5-4-6-10-10
Cash Flow From Investing Activity -4-9-2-41-9-10010-6-15
Capex -5-12-5-6-5-4-3-6-10-17
Net Investments -10000-20000
Others 33415-2-971642
Cash Flow From Financing Activity -155-11-7-11-40138-26-246
Net Proceeds from Shares 000000126001
Net Proceeds from Borrowing 0-140-0-0-900-02
Interest Paid -10-10-7-5-6-4-3-3-5-4
Dividend Paid 00000-6-6-14-14-14
Others -528-4-2-5-2021-9-521
Net Cash Flow 0-0-0-000-01514

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)6.524.372.316.125.019.853.758.078.546.35
ROCE (%)9.459.55.288.677.9813.575.649.4411.368.63
Asset Turnover Ratio0.680.620.510.640.560.690.520.560.660.51
PAT to CFO Conversion(x)1.730.442.40.920.912.13-3.170.5510.85
Working Capital Days
Receivable Days475869608975979693121
Inventory Days41536551685662605371
Payable Days128137154109134106119107102136

Kopran Ltd Stock News

Kopran Ltd FAQs

The current trading price of Kopran on 05-Dec-2025 16:59 is ₹135.6.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Kopran stood at ₹674.5.
The latest P/E ratio of Kopran as of 04-Dec-2025 is 43.44.
The latest P/B ratio of Kopran as of 04-Dec-2025 is 1.62.
The 52-week high of Kopran is ₹227.1 and the 52-week low is ₹123.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kopran is ₹241.6 ( Cr.) .

About Kopran Ltd

The company was incorporated on April 26, 1958 as a private limited company under the name Kopran Chemical Company Pvt. Ltd. by Ramanlal V Shah Sevantilal, A Shah , Chimanlal G Sheth and Jivanalal M Shah. In 1972, the company’s management was acquired by Chemo Pharma Laboratories Ltd and the Company’s products were marketed by them.

Promoted by the Parijat Enterprises, Kopran is currently an integrated health care company. Kopran has used research-based technology to contribute towards total health-care. The company started modestly as a Semi Synthetic Penicillin (SSP) player and expanded to becomes the largest SSP Player in India with an annual SSP facility of over 1200 tones per annum.Subsequently the SSP business was hived off into a separate Company in a joint venture with Synpac Pharmaceuticals Ltd, UK.Kopran Laboratories Ltd. markets and supports high-tech life-saving medical equipments and diagnostics reagents since 1988.

Kopran Research Laboratories Ltd. (KRLL) is an emerging research organisation with particular interests in the areas of drug discovery, polymer technology and synthesis of new molecules.

Kopran is working towards creating and maintaining a global presence.Presence in Africa through Kampala Pharmaceutical Industries (KPI),a pharmaceutical company engaged in the manufacture and marketing of finished dosage forms in Uganda.

The company is having presence in the Middle East Market through a joint venture with Dubai Investment Corporation a leading investment company in Dubai for the manufacture and marketing of finished dosage forms in Dubai.

KRLL is a 100% subsidiary of Kopran Ltd.  KRLL is recognised by the Department of Science and Industrial Research (DSIR), Government of India. The company is staffed with competent and dedicated team of scientists.

Product range of the company includes:

Finished Dosage Forms

  • Antibiotics/antibacterials
  • Anti-malarial
  • Cadiovasculars
  • Pain management
  • Anthelminthics
  • Antiprotozoals
  • Antidiabetics
  • Gastrointestinals
  • Drug for erectile dysfuntion
  • Antiallergics
  • Respiratory/anti-asthmatics
  • Metered dose inhalers
  • Dry powder inhalers
  • Antiviral

Active Pharmaceutical Ingredients

  • Anti-hypertensives
  • Macrolides
  • Taste Masked
  • Cephalosporins 
  • Under Development
  • Others

Achievements/ recognition:

  • Kopran has a state of art manufacturing plants (Penicillin & General) approved by: -MCC (South Africa) -TGA, Australia and FDA, USA are in the pipeline

Future plans:

  • Brand Equity Development
  • Research for New Chemical Entities
  • Globalise its operations thus making Kopran a truly International Pharmaceutical Company.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×